Literature DB >> 17151110

Replication and propagation of attenuated vesicular stomatitis virus vectors in vivo: vector spread correlates with induction of immune responses and persistence of genomic RNA.

Ian D Simon1, Jean Publicover, John K Rose.   

Abstract

Live-attenuated vesicular stomatitis virus (VSV) vectors expressing foreign antigens induce potent immune responses and protect against viral diseases in animal models. Highly attenuated (VSV-CT1) or single-cycle VSV (VSVDeltaG) vectors induce immune responses lower than those generated by attenuated wild-type VSV vectors when given intranasally. We show here that reduced spread of the more highly attenuated or single-cycle vectors to other organs, including lymph nodes, correlates with the reduction in the immune responses. A reverse transcription, real-time PCR assay for VSV genomic RNA (gRNA) sequences showed long-term persistence of gRNA from replicating vectors in lymph nodes, long after viral clearance. Such persistence may be important for induction of potent immune responses by VSV vectors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17151110      PMCID: PMC1797556          DOI: 10.1128/JVI.02525-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.

Authors:  Michael A Egan; Siew Yen Chong; Nina F Rose; Shakuntala Megati; Kevin J Lopez; Eva B Schadeck; J Erik Johnson; Amjed Masood; Priscilla Piacente; Robert E Druilhet; Paul W Barras; Dana L Hasselschwert; Patricia Reilly; Eric M Mishkin; David C Montefiori; Mark G Lewis; David K Clarke; R Michael Hendry; Preston A Marx; John H Eldridge; Stephen A Udem; Zimra R Israel; John K Rose
Journal:  AIDS Res Hum Retroviruses       Date:  2004-09       Impact factor: 2.205

2.  Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies.

Authors:  B Schlereth; J K Rose; L Buonocore; V ter Meulen; S Niewiesk
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  Requirement for a non-specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus.

Authors:  M J Schnell; L Buonocore; E Boritz; H P Ghosh; R Chernish; J K Rose
Journal:  EMBO J       Date:  1998-08-10       Impact factor: 11.598

4.  Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection.

Authors:  M J Schnell; J E Johnson; L Buonocore; J K Rose
Journal:  Cell       Date:  1997-09-05       Impact factor: 41.582

5.  Attenuated vesicular stomatitis viruses as vaccine vectors.

Authors:  A Roberts; L Buonocore; R Price; J Forman; J K Rose
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

6.  Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.

Authors:  Steven M Jones; Heinz Feldmann; Ute Ströher; Joan B Geisbert; Lisa Fernando; Allen Grolla; Hans-Dieter Klenk; Nancy J Sullivan; Viktor E Volchkov; Elizabeth A Fritz; Kathleen M Daddario; Lisa E Hensley; Peter B Jahrling; Thomas W Geisbert
Journal:  Nat Med       Date:  2005-06-05       Impact factor: 53.440

7.  Persistent antigen presentation after acute vesicular stomatitis virus infection.

Authors:  Damian L Turner; Linda S Cauley; Kamal M Khanna; Leo Lefrançois
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

8.  A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector.

Authors:  Jean Publicover; Elizabeth Ramsburg; John K Rose
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

9.  Vesicular stomatitis New Jersey virus RNA persists in cattle following convalescence.

Authors:  G J Letchworth; J C Barrera; J R Fishel; L Rodriguez
Journal:  Virology       Date:  1996-05-15       Impact factor: 3.616

10.  Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine.

Authors:  Sagar U Kapadia; John K Rose; Elaine Lamirande; Leatrice Vogel; Kanta Subbarao; Anjeanette Roberts
Journal:  Virology       Date:  2005-09-30       Impact factor: 3.616

View more
  32 in total

Review 1.  Viruses - from pathogens to vaccine carriers.

Authors:  Juliana C Small; Hildegund C J Ertl
Journal:  Curr Opin Virol       Date:  2011-10       Impact factor: 7.090

2.  Quantitative PCR technique for detecting lymphocytic choriomeningitis virus in vivo.

Authors:  Megan M McCausland; Shane Crotty
Journal:  J Virol Methods       Date:  2007-10-17       Impact factor: 2.014

3.  Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination.

Authors:  Hok Hei Tam; Mariane B Melo; Myungsun Kang; Jeisa M Pelet; Vera M Ruda; Maria H Foley; Joyce K Hu; Sudha Kumari; Jordan Crampton; Alexis D Baldeon; Rogier W Sanders; John P Moore; Shane Crotty; Robert Langer; Daniel G Anderson; Arup K Chakraborty; Darrell J Irvine
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-04       Impact factor: 11.205

4.  Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.

Authors:  Marlena M Westcott; Jingfang Liu; Karishma Rajani; Ralph D'Agostino; Douglas S Lyles; Mercedes Porosnicu
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

5.  Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV.

Authors:  Koen K A Van Rompay; Kristina Abel; Patricia Earl; Pamela A Kozlowski; Juliet Easlick; Joseph Moore; Linda Buonocore-Buzzelli; Kimberli A Schmidt; Robert L Wilson; Ian Simon; Bernard Moss; Nina Rose; John Rose; Marta L Marthas
Journal:  Vaccine       Date:  2009-12-06       Impact factor: 3.641

6.  Characterization of a single-cycle rabies virus-based vaccine vector.

Authors:  Emily A Gomme; Elizabeth J Faul; Phyllis Flomenberg; James P McGettigan; Matthias J Schnell
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

7.  In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation.

Authors:  J Erik Johnson; John W Coleman; Narender K Kalyan; Priscilla Calderon; Kevin J Wright; Jennifer Obregon; Eleanor Ogin-Wilson; Robert J Natuk; David K Clarke; Stephen A Udem; David Cooper; R Michael Hendry
Journal:  Vaccine       Date:  2009-03-13       Impact factor: 3.641

8.  A chimeric vesiculo/alphavirus is an effective alphavirus vaccine.

Authors:  Anasuya Chattopadhyay; Eryu Wang; Robert Seymour; Scott C Weaver; John K Rose
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

9.  Interferon-induced protein Ifit2 protects mice from infection of the peripheral nervous system by vesicular stomatitis virus.

Authors:  Volker Fensterl; Jaime L Wetzel; Ganes C Sen
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

10.  Role of peripheral immune response in microglia activation and regulation of brain chemokine and proinflammatory cytokine responses induced during VSV encephalitis.

Authors:  Christina D Steel; Kimberly Breving; Susan Tavakoli; Woong-Ki Kim; Larry D Sanford; Richard P Ciavarra
Journal:  J Neuroimmunol       Date:  2013-12-11       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.